Details

Autor(en) / Beteiligte

• Schettini, Francesco
• Chic, Nuria
• Brasó-Maristany, Fara
• Paré, Laia
• Pascual, Tomás
• Conte, Benedetta
• Martínez-Sáez, Olga
• Adamo, Barbara
• Vidal, Maria
• Barnadas, Esther
• Fernández-Martinez, Aranzazu
• González-Farre, Blanca
• Sanfeliu, Esther
• Cejalvo, Juan Miguel
• Perrone, Giuseppe
• Sabarese, Giovanna
• Zalfa, Francesca
• Peg, Vicente
• Fasani, Roberta
• Villagrasa, Patricia
• Gavilá, Joaquín
• Barrios, Carlos H.
• Lluch, Ana
• Martín, Miguel
• Locci, Mariavittoria
• De Placido, Sabino
• Prat, Aleix

Titel

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Ist Teil von

• NPJ breast cancer, 2021-01, Vol.7 (1), p.1-1, Article 1

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.